LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

90.51 3.71

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

86.37

Máximo

90.55

Métricas clave
By Trading Economics
Ingresos	-8.1M -56M
Ventas	2.9M 60M
BPA	-0.83
Margen de beneficios	-92.559
Empleados	414
EBITDA	-9.7M -52M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+57.83% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	151M 6B
Apertura anterior	86.8
Cierre anterior	90.51

Noticias sobre sentimiento de mercado

By Acuity

100%

329 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

60 / 65.58 Soporte y Resistencia

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 may 2026, 20:36 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 may 2026, 22:02 UTC

Ganancias

ZTO Express (Cayman): Di Xu to Resign From Board

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 may 2026, 22:00 UTC

Ganancias

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 may 2026, 21:37 UTC

Ganancias

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 may 2026, 21:01 UTC

Ganancias

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 may 2026, 20:58 UTC

Ganancias

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 may 2026, 20:46 UTC

Acciones populares

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 may 2026, 20:43 UTC

Charlas de Mercado

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 may 2026, 20:34 UTC

Ganancias

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q EPS 5c >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q Sales $1.4B >JHX

19 may 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5B

19 may 2026, 20:18 UTC

Charlas de Mercado

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 may 2026, 19:23 UTC

Charlas de Mercado

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

57.83% repunte

Estimación a 12 Meses

Media 137.64 USD 57.83%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentimiento

By Acuity

329 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.